[1]閆雪波,王 炯.RKIP在不同類型肺癌中表達的變化及臨床意義[J].醫學信息,2019,(22):55-58.[doi:10.3969/j.issn.1006-1959.2019.22.018]
 YAN Xue-bo,WANG Jiong.Changes of RKIP Expression in Different Types of Lung Cancer and Its Clinical Significance[J].Medical Information,2019,(22):55-58.[doi:10.3969/j.issn.1006-1959.2019.22.018]
點擊復制

RKIP在不同類型肺癌中表達的變化及臨床意義()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
55-58
欄目:
論著
出版日期:
2019-11-15

文章信息/Info

Title:
Changes of RKIP Expression in Different Types of Lung Cancer and Its Clinical Significance
文章編號:
1006-1959(2019)22-0055-04
作者:
閆雪波王 炯
(安徽醫科大學第一附屬醫院干部呼吸與危重醫學科,安徽 合肥 230022)
Author(s):
YAN Xue-boWANG Jiong
(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,Anhui,China)
關鍵詞:
RKIPERK1/2肺癌腺癌癌癥分期
Keywords:
RKIPERK1/2Lung cancerAdenocarcinomaCancer staging
分類號:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.22.018
文獻標志碼:
A
摘要:
目的 觀察Raf激酶抑制蛋白(RKIP)在不同類型肺癌中表達的變化及探討其臨床價值。方法 選取鱗癌21例、腺癌23例及小細胞肺癌10例設為實驗組,肺良性病變10例設為對照組,采用免疫組化的方法檢測RKIP的表達,觀察在不同類型肺癌中表達的差異及與臨床分期的關系。結果 與對照組比較,實驗組中RKIP的表達水平均降低,差異有統計學意義(P<0.05)。實驗組中RKIP的表達最低的是小細胞癌,其次為鱗癌,再次腺癌。對腺癌進一步研究發現,與Ⅰ及Ⅱ期比較,RKIP在Ⅲ及Ⅳ期的表達更低;與Ⅰ期比較,RKIP在Ⅱ期中表達稍有減低,但差異無統計學意義(P>0.05);與Ⅲ期比較,RKIP在Ⅳ期中表達稍有減低,但差異無統計學意義(P>0.05)。磷酸化ERK1/2(p-ERK1/2)的表達趨勢與RKIP相反,與Ⅰ和Ⅱ期比較,在Ⅲ和Ⅳ期中表達明顯升高。相關性分析顯示,RKIP與p-ERK1/2的表達呈負相關(r=-0.893,P<0.05)。結論 RKIP表達水平的缺失可能促進了ERK1/2的磷酸化,從而促進了肺癌的發生及發展,因此檢測RKIP的表達水平可能對診斷肺癌及分期預后有重要的臨床價值。
Abstract:
Objective To observe the changes of expression of Raf kinase inhibitory protein (RKIP) in different types of lung cancer and to explore its clinical value. Methods 21 cases of squamous cell carcinoma, 23 cases of adenocarcinoma and 10 cases of small cell lung cancer were selected as experimental group. 10 cases of benign lung lesions were used as control group. The expression of RKIP was detected by immunohistochemistry and observed in different types of lung cancer. Differences and relationships with clinical staging. Results Compared with the control group, the expression level of RKIP in the experimental group decreased,the difference was statistically significant (P<0.05). The lowest expression of RKIP in the experimental group was small cell carcinoma, followed by squamous cell carcinoma and re-adenocarcinoma. Further studies on adenocarcinoma found that RKIP was lower in stage III and IV than stage I and stage II. Compared with stage I, RKIP was slightly decreased in stage II, but the difference was not statistically significant (P>0.05). Compared with stage III, RKIP expression was slightly decreased in stage IV, but the difference was not statistically significant (P>0.05). The expression trend of phosphorylated ERK1/2 (p-ERK1/2) was opposite to that of RKIP, and the expression was significantly increased in stages III and IV compared with stage I and II. Correlation analysis showed that RKIP was negatively correlated with p-ERK1/2 expression (r=-0.893, P<0.05). Conclusion The loss of RKIP expression may promote the phosphorylation of ERK1/2, which promotes the occurrence and development of lung cancer. Therefore, the detection of RKIP expression may have important clinical value in the diagnosis of lung cancer and staged prognosis.

參考文獻/References:

[1]陸方曉,阮磊.肺癌的CT征象與表皮生長因子受體基因突變相關性的研究進展[J].實用醫學影像雜志,2019,20(2):167-170. [2]Roberts PJ,Der CJ.Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer[J].Oncogene,2007,26(22):3291-3310. [3]支修益,石遠凱,于金明.中國原發性肺癌診療規范(2015年版)[J].中華腫瘤雜志,2015,37(1):67-78. [4]周凱,張穎異,岑瑛,等.Raf激酶抑制蛋白對惡性黑色素瘤細胞增殖、遷移的影響及其機制[J].中華醫學雜志,2019,99(8):616-620. [5]Wang A,Duan G,Zhao C,et al.Reduced RKIP expression levels are associated with frequent non-small cell lung cancer metastasis andSTAT3 phosphorylation and activation[J].Oncology letters,2017,13(5):3039-3045.

更新日期/Last Update: 2019-11-15
中国足彩网竞彩